Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for Pain in MDD
NCT02232555Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2005
- Primary completion
- May 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Duloxetine with Placebo (2 arms). Primary endpoint: Change in Brief Pain Inventory Short Form 24-hour Average Pain Score at 8 weeks. Started May 2005; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02232555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232555.